These results demonstrated again the improved antitumor effect of vemurafenib upon co-use with melatonin in melanoma treatment, and also confirmed the involvement of p65/iNOS/hTERT signaling in the co-treatment-mediated regulation of melanoma growth and CSC expansion. The gene discussed is NOS2; the disease is melanoma.